文献速递哮喘

单剂本瑞利珠单抗后哮喘控制、气道黏液与129Xe MRI通气

Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose.
PubMed 文献 · Chest · 2022-03-10

本研究在29例嗜酸性哮喘患者中,于单次30 mg皮下注射本瑞利珠单抗前及第28天进行129Xe MRI、CT黏液栓评分、血嗜酸性粒细胞计数、肺功能及哮喘控制问卷评估。结果显示第28天血嗜酸性粒细胞、VDP、ACQ-6、AQLQ及外周气道阻力均显著改善;在黏液栓≥5个的亚组中VDP和ACQ-6显著改善,而<5个的亚组未观察到。

要点

  • 单剂本瑞利珠单抗可显著改善嗜酸性哮喘患者129Xe MRI通气缺陷百分比和哮喘控制。
  • 基线VDP和CT黏液栓评分是第28天ACQ-6改善的显著预测变量。
  • 黏液栓负荷高的患者可能从本瑞利珠单抗的气道功能改善中获益更明显。

核心结论

  • 单剂本瑞利珠单抗后,未控制嗜酸性哮喘患者及有明显黏液栓患者的129Xe通气显著改善。

研究设计与样本

  • 前瞻性研究,29例参与者(27例有基线CT)完成第0天和第28天访视,单次30 mg皮下注射本瑞利珠单抗。

主要发现

  • 第28天所有参与者血嗜酸性粒细胞计数、VDP、ACQ-6评分、AQLQ评分(均P < .001)及外周气道阻力(P = .04)显著改善。
  • 第28天,黏液栓≥5个的9例亚组VDP和ACQ-6评分显著改善,而黏液栓<5个的18例亚组未显著改善。
  • 多变量模型显示第0天VDP(P < .001)和第0天CT黏液评分(P < .001)是第28天ACQ-6评分变化的显著变量。

临床怎么用

  • 对于未控制嗜酸性哮喘患者,单剂本瑞利珠单抗后可用129Xe MRI VDP和CT黏液评分评估气道功能反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with eosinophilic asthma often report poor symptomatic control and quality of life. Anti-IL-5 therapy, including anti-IL-5Rα (benralizumab), rapidly depletes eosinophils in the blood and airways and also reduces asthma exacerbations and improves quality of life scores. In patients with severe asthma, eosinophilic inflammation-driven airway mucus occlusions have been measured using thoracic x-ray CT imaging. Pulmonary 129Xe MRI ventilation defect percentage (VDP) also sensitively measures asthma airway dysfunction caused by airway hyperresponsiveness, remodeling, and luminal mucus occlusions. Using 129Xe MRI and CT imaging together, it is feasible to measure both airway luminal occlusions and airway ventilation in relationship to anti-IL-5 therapy to ascertain the direct impact of therapy-induced eosinophil depletion on airway function. RESEARCH QUESTION: Does 129Xe MRI detect airway functional responses to eosinophil depletion after a single benralizumab dose and do airway mucus occlusions mediate this response? STUDY DESIGN AND METHODS: MRI, eosinophil count, spirometry, oscillometry, Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ), and St. George's Respiratory Questionnaire were completed on day 0 and 28 days after a single 30-mg subcutaneous benralizumab dose. CT scan mucus plugs were scored on day 0, and MRI VDP was quantified on days 0 and 28. RESULTS: Twenty-nine participants (27 with baseline CT imaging) completed day 0 and day 28 visits. On day 28 after a single benralizumab dose, significantly improved blood eosinophil counts, VDP, ACQ 6 scores, AQLQ scores (all P < .001), and peripheral airway resistance (P = .04) were found in all participants. On day 28, significantly improved VDP and ACQ 6 scores also were found in the subgroup of nine participants with five or more mucus plugs, but not in the subgroup (n = 18) with fewer than five mucus plugs. Based on univariate relationships for change in ACQ 6 score, multivariate models were generated and showed that day 0 VDP (P < .001) and day 0 CT scan mucus score (P < .001) were significant variables for change in ACQ 6 score on day 28 after benralizumab injection. INTERPRETATION: 129Xe ventilation significantly improved in participants with uncontrolled asthma and in those with significant mucus plugging after a single dose of benralizumab. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03733535; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. McIntosh MJ, Kooner HK, Eddy RL, et al. Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose. Chest. 2022. PMID: 35283104. doi:10.1016/j.chest.2022.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。